(Total Views: 382)
Posted On: 04/23/2019 9:58:02 AM
Post# of 72441
Is that what I missed in this PR, that the fact that it was in JAMA basically gave us third party confirmation for B-OM? If so, changes my mind as to the value of the PR. Is this JAMA article likely to get a lot more eyes on B-OM or even potentially speed up the time for a partner to step to the plate? Hope so.
Guess my frustration is the fact that it seems we have to beat BP over the head to realize what a wonderful treatment B-OM is when they have the clinical results staring them in the face. Also chaps me that they have no problem throwing lots of money at other drugs that were woefully inadequate in both safety and efficacy and also much earlier in the trial cycle but they want the B-OM drug to be almost into P3 before they come up with a decent deal to acquire the property.
Guess my frustration is the fact that it seems we have to beat BP over the head to realize what a wonderful treatment B-OM is when they have the clinical results staring them in the face. Also chaps me that they have no problem throwing lots of money at other drugs that were woefully inadequate in both safety and efficacy and also much earlier in the trial cycle but they want the B-OM drug to be almost into P3 before they come up with a decent deal to acquire the property.
(1)
(0)Scroll down for more posts ▼
